Abstracts tagged "gout"

Abstract Number: 1030 • 2018 ACR/ARHP Annual Meeting
Parenteral Injection of Human Adipose-Derived Mesenchymal Stem Cells Attenuates Inflammation in an Acute Model of Gouty Arthritis
Juan Pablo Medina¹, Sandra Perez-Baos¹, Esperanza Naredo², Alberto Lopez-Reyes³, Gabriel Herrero-Beaumont⁴ and Raquel Largo⁴, ¹Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Synovial fluid analysis department, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ⁴Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain
Background/Purpose: The regenerative and immunomodulatory properties of Adipose-Derived Mesenchymal Stem Cells (ASCs) make them a potential therapeutic approach for the treatment of chronic inflammatory diseases,…
Abstract Number: 1289 • 2018 ACR/ARHP Annual Meeting
Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population
Andrew Milgroom¹, Mara Onita Lenco¹, Kevin Francis¹, Jeffrey D. Kent², Brian LaMoreaux³ and Brian F. Mandell⁴, ¹Trinity Partners, Waltham, MA, ²Medical Affairs, Horizon Pharma USA, Inc, Lake Forest, IL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Gout is a frequent co-morbidity of solid organ transplant (SOT). Cyclosporine (CsA) is often cited as the main cause of gout in SOT, as…
Abstract Number: 2252 • 2018 ACR/ARHP Annual Meeting
Serum Urate Ant Its Clearance in Patients with Chronic Kidney Disease Under Peritoneal Dialysis
Claudia Diez¹, Javier Pérez-Contreras^1,2 and Mariano Andrés^1,3, ¹Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ²Servicio de Nefrología, Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ³Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: Hyperuricemia and gout are common in patients with chronic kidney disease (CKD), some ultimately requiring replacement therapy. Serum urate (SU) levels appear to achieve…
Abstract Number: 1031 • 2018 ACR/ARHP Annual Meeting
Orally Administered Cherry Juice Inhibits Localized Nfκb Activity and Histopathological Infiltrates in a Murine Model of Gout
Nicholas A. Young¹, Peter Harb², Ifeoma Okafor³, Caitlin Henry², Emily Schwarz², Kyle Jablonski⁴, Bianca Sandoval², Wael Jarjour⁵ and Naomi Schlesinger⁶, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Rheumatology and Immunology, Columbus, OH, ³Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Department of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Gout is caused by the inflammation induced from the precipitation of monosodium urate (MSU) crystals in joints and is the most common inflammatory arthritis…
Abstract Number: 1290 • 2018 ACR/ARHP Annual Meeting
Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study
Silvia Rollefstad¹, Till Uhlig^2,3, Lars Fridtjof Karoliussen³, Hilde B. Hammer⁴ and Anne Grete Semb⁵, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²University of Oslo, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Systemic inflammation and atherosclerosis in patients with gout. Results from the NOR-Gout studyBackground/Purpose: The association between gout and cardiovascular disease (CVD) is well known, whereas…
Abstract Number: 2254 • 2018 ACR/ARHP Annual Meeting
Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: Svp-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing
Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, but are limited by their immunogenicity. We have previously shown that synthetic…
Abstract Number: 1124 • 2018 ACR/ARHP Annual Meeting
Epidemiological Characteristics of Inpatient Admissions for Acute Inflammatory Gout Arthropathy and Factors Affecting Length of Stay: A National Level Study
Vagishwari Murugesan and Jennifer Tran, Internal Medicine, Medstar Washington Hospital Center, Washington, DC
Background/Purpose:Gout is a common cause of inflammatory arthritis due to accumulation of monosodium urate crystals in joints, bones and soft tissues. The aim of the…
Abstract Number: 1294 • 2018 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin Enables Sustained Reduction of Acute Gout Flares
Rehan Azeem¹, Alan J. Kivitz², Earl Sands¹, Wesley DeHaan Ph.D.³, Lloyd Johnston³ and Takashi Kei Kishimoto³, ¹Selecta Biosciences, Inc, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Watertown, MA
Background/Purpose: Pegylated uricases are therapies for treatment of severe chronic gout, particularly for rapid tophi resolution. However, uricases are limited by induction of anti-drug antibodies…
Abstract Number: 2255 • 2018 ACR/ARHP Annual Meeting
Increased Cost Burden in an Early Diagnosed Cohort of Uncontrolled Versus Controlled Gout: Analysis of a Large US Payer Database
Brian LaMoreaux¹, Megan Francis-Sedlak² and Robert J Holt², ¹Horizon Pharma USA, Inc, Lake Forest, IL, ²Horizon Pharma USA, Inc., Lake Forest, IL
Background/Purpose: Gout is a progressive systemic inflammatory disease that is widely prevalent, estimated to effect 3.9% or 8.3 million people of the United State (US)…
Abstract Number: 1131 • 2018 ACR/ARHP Annual Meeting
The Prevalence and Incidence of Gout, Its Associated Comorbidities and Treatment Pattern: An Epidemiological Study from Germany
Uta Kiltz¹, Fernando Perez-Ruiz², Till Uhlig³, Tim L. Jansen⁴, Ravichandra Karra Gurunath⁵, Niklas Schmedt⁶, Wolfgang Galetzka⁶, Gudula Petersen⁵, Tonio Schoenfelder⁷ and Anne-Kathrin Tausche⁸, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University, Bochum, Herne, Germany, ²BioCruces Health Research Institute, Barakaldo, Spain, ³University of Oslo, Oslo, Norway, ⁴Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, ⁵Grünenthal GmbH, Aachen, Germany, ⁶InGef – Institute for Applied Health Research, Berlin, Germany, ⁷Institute for Applied Health Services Research, Berlin, Germany, ⁸Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany
Background/Purpose: The most common type of inflammatory arthritis in Germany is gout, however the last epidemiological study was done a decade ago (Annemanns, 2007). This…
Abstract Number: 1296 • 2018 ACR/ARHP Annual Meeting
A Novel Potent and Selective Urate Transporter 1 Inhibitor, NC-2700, with pH-Raising Effect on Low Urinary pH
Masuharu Hirano¹, Takafumi Muto¹, Toshitake Hirai², Promsuk Jutabha³, Naohiko Anzai⁴, Toru Horie⁵, Hitoshi Endou⁶ and Tomio Yamakawa⁷, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ³Dokkyo Medical University School of Medicine, Tochigi, Japan, ⁴Chiba University Graduate School of Medicine, Chiba, Japan, ⁵Dethree Res Lab Inc., Tsukuba, Japan, ⁶J-Pharma Co., Ltd., Yokohama, Japan, ⁷Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: In most patients with gout, renal underexcretion of uric acid is the main mechanism for hyperuricemia. However, for the risk of uric acid kidney…
Abstract Number: 2847 • 2018 ACR/ARHP Annual Meeting
Associations between Serum Uric Acid Level and Coronary Artery Disease
Patricia Kachur^1,2, Satish Tadepalli³, Sergey Kachur⁴ and Pramil Cheriyath³, ¹Rheumatolgy, Ochsner Foundation Hospital, New Orleans, LA, ²Internal Medicine, Ocala Regional Medical Center, Ocala, FL, ³Hackensack Meridian Health, Ocean Medical Center, Brick, NJ, ⁴Ocala Regional Medical Center, Ocala, FL
Title: Association between Serum Uric Acid Level and Coronary Artery DiseaseBackground/Purpose: Previous studies have shown an unclear relationship between serum uric acid (SUA) and coronary…
Abstract Number: 1132 • 2018 ACR/ARHP Annual Meeting
Diet Modification for Gout Patients: Effects on Gout Attacks and Risk Factors for Metabolic Syndrome
Michelle DiFiore¹, Maida Wong² and Juliana Chang³, ¹Internal Medicine, University of California, Irvine, School of Medicine, Orange, CA, ²Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA, ³UC Irvine Medical Center, Orange, CA
Background/Purpose: Gout affects 8 million individuals in the US and is prevalent among patients with metabolic syndrome. Although there are many medications to control gout…
Abstract Number: 1297 • 2018 ACR/ARHP Annual Meeting
Risk of Dementia in Patients with Gout and the Impact of Urate-Lowering Therapies: A Large Population-Based Cohort Study
Louise Crowley, Alyshah Abdul Sultan, Edward Roddy, Christian Mallen, Joanne Protheroe and Lorna Clarson, Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom
Background/Purpose: Evidence is conflicting concerning dementia risk in gout patients, with hyperuricaemia proposed to exert a neuroprotective effect. Serum urate (sUA) targets guiding urate-lowering therapies…
Abstract Number: 2964 • 2018 ACR/ARHP Annual Meeting
Detection of Uric Acid Crystals in the Vasculature of Patients with Gout Using Dual-Energy Computed Tomography
Sharon Barazani¹, WeiWei Chi², Renata Pyzik³, Adam Jacobi⁴, Tom O'Donnell⁵, Zahi Fayad³, Venkatesh Mani³ and Yousaf Ali², ¹Medical School, Icahn School of Medicine at Mount Sinai, New York, NY, ²Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Translational and Molecular Imaging Institute (TMII), Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Siemens Healthcare, New York, NY
Background/Purpose: Many recent studies have shown an association between gout and increased cardiovascular risk, however the mechanism by which this occurs is unclear. Dual-Energy Computed…

1
2
3
…
20
Next Page »